SCHEMBL1198342

SCHEMBL1198342

Cc1sc(-c2cccc(C(F)(F)F)c2)nc1CI

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
MAPT P10636 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
PPARA Q07869 3/20 0.47
PPARG P37231 2/20 0.47
DCK P27707 1/20 0.46
ALPL P05186 1/20 0.42
ALPI P09923 1/20 0.42
PPARD Q03181 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
DGAT2 Q96PD7 1/20 0.40
IKBKB O14920 1/20 0.39
BRD4 O60885 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1199289 0.86 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL12876901 0.81 DCK (0.47) ALDH1A1MAPTMEN1KMT2APPARA
SCHEMBL2094451 0.81 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL1198871 0.80 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL2094449 0.79 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL1198904 0.78 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL16398991 0.76 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL1198527 0.75 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL1199183 0.75 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL13650688 0.74 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102056907-B Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL 2014-12-31 CN disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
CN-102056907-A Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL 2011-05-11 CN disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A ALDH1A1 1037/4885SMN1; SMN2 2057/4885MAPT 4667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.